MarkBishton

Dr. Mark Bishton

Nottingham University Hospitals NHS Trust

Department of Clinical Haematology
 

Contact

 
Derby Road
NG7 2UH Nottingham
 
+44 115 9529972
 

Literature

Publications (*** = Impact Factor >5)

I have 56 publications, 20 first author publications, 13 second author publications and five last author publications. Two publications have impact factors >10 and 18 publications have an impact factor >5. I have been cited over 1200 times with a H index of 16.

  1. ***Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: The safety run-in of the phase 3 SYMPATICO study. Michael Wang, Radhakrishnan Ramchandren, Robert Chen, Lionel Karlin,4 Geoffrey Chong, Wojciech Jurczak, Ka Lung Wu, Mark Bishton et al*** Journal of Hematology & Oncology in press [IF 11.059] ***
  2. ***Population-based cohort study of the efficacy of Brentuximab-Vedotin in relapsed systemic Anaplastic Large Cell Lymphoma using Public Health England data. Sarah J Halligan, Matthew J Grainge, Nicolas Martinez-Calle, Christopher P Fox, Mark J Bishton. Brit J Haem in press. [IF 6.998] *** 
  3. ***A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data. Mark Bishton, Peter Stilwell, Dr Tim R Card, Peter Lanyon, Lu Ban, Lucy Elliss-Brookes, Jessica Manson,  Vasanta Nanduri, Kate Earp, Luke Flower, Raj Amarnani, Judith Rankin, Ethan S Sen, Rachel S Tattersall Colin J Crooks, Jeanette Aston, Veronika Siskova, Joe West, Mary Bythell. Brit J Haem. 2021 August 12. doi.org/10.1111/bjh.17768.  [IF 6.998] ***
  4. ***Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma (PCNSL) treated at a single referral centre in the United Kingdom. Kaji FA, Martinez-Calle N, Bishton MJ, Figueroa R, Adlington J, O’Donoghue M, Smith S, Byrne P, Paine S, Sovani V, Auer D, James E, Bessell EM, Grainge MJ, Fox CP. Brit J Haem. 2021 Aug 8. doi: 10.1111/bjh.17747. [IF 6.998] ***
  5. Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Martinez-Calle N, Kirkwood AA, Lamb M, Smith A, Khwaja J, Manos K, Shrubsole C, Gray N, Lewis K, Tivey A, Bishton MJ et al. Adv Ther. 2021 May 26. doi: 10.1007/s12325-021-01764-0. [IF 3.871]
  6. ***Treatment patterns and outcomes of elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis. Alexandros Rampotas, Matthew R. Wilson, Oliver Lomas, Nicholas Denny, Heather Leary, Graeme Ferguson, Pamela McKay, Tim Ebsworth, Jonathan Miller, Nimish Shah, Nicolas Martinez-Calle, Mark Bishton et al. Brit J Haem. 2021 Jul;194(2):365-377. doi: 10.1111/bjh.17513. Epub 2021 May 7. [IF 6.998] ***
  7. Infection-related morbidity and mortality for elderly DLBCL patients treated with full or attenuated dose R-CHOP. Toby Eyre, William Wilson, Amy Kirkwood, JuliaWolf, Catherine Hildyard, Hannah Plaschkes, John Griffith, Paul Fields, Arief Gunawan, Rebecca Oliver, Stephen Booth, Jaimal Kothari, Christopher Fox, Nicolás Martinez-Calle, Andrew McMillan, Mark Bishton, Graham Collins, and Chris Hatton. Blood Adv. 2021 2021 Apr 27;5(8):2229-2236. [IF 4.910]
  8. ***The Diagnostic and Therapeutic Challenges of Grade 3B Follicular Lymphoma. Allison Barraclough, Mark Bishton, Chan Y Cheah, Diego Villa, Eliza Hawkes. Brit J Haem. Mar 11. doi: 10.1111/bjh.17404. Online ahead of print. [IF 6.998] ***
  9. ***Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. Rory McCulloch, David Lewis, Nicola Crosbie, Toby A. Eyre, Simon Bolam, Anita Arasaretnam, Thomas Creasey, Harshita Goradia, Annabel McMillan, Safia Dawi, Samuel Harrison, Oliver Miles, Andrew Robinson, David Dutton, Matthew R. Wilson, Pam McKay, George Follows, Neil Phillips, Russell Patmore, Jonathan Lambert, Mark Bishton et al. Brit J Haem. 2021 Apr;193(2):290-298. doi: 10.1111/bjh.17363. Epub 2021 Feb 23. [IF 5.518] ***
  10. Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax. Figueroa Mora, Rocio; Martinez-Calle, Nicolas; Prescott Katie; Bishton, Mark EJHaem. 2020 Nov;1(2):418-419 [IT TBD]
  11. Extended follow-up of CD4+ T cell recovery kinetics in a large cohort of patients with B-cell lymphoproliferative disease treated with Rituximab-Bendamustine. Gaiolla R, Hartley S, Beech A, Knight H, Smith D, Bishton M, Fox CP, Martinez-Calle N. Hematological Oncology. Hematol Oncol. 2020 Aug 29. doi: 10.1002/hon.2797. Online ahead of print. [IF 2.832]
  12. A comparison of bendamustine-EAM versus BEAM conditioning for autogolous stem cell transplant in lymphoma. Glover, Alexander; Fox, Christopher Paul; Mcmillan, Andrew; Beech, Amy; Martinez-Calle, Nicholas; Griffiths, Catherine; Richardson, Faith; Russell, Nigel; Bishton, Mark. Leuk Lymphoma. 2020 Dec;61(14):3529-3531. doi: 10.1080/10428194.2020.1811863. [IF 2.969]
  13. ***The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: Molecular response strongly predicts prolonged overall survival. Mark Bishton, Simon Rule, William Wilson, Deborah Turner, Russell Patmore, Laura Clifton-Hadley, Andrew McMillan, Richard Lush, Andrew Haynes. [2020 Mar 9. doi: 10.1111/bjh.16555.  Br J Haematol. 2020 Aug;190(4):545-554. [IF 5.518]
  14. Outcome in Patients with Diffuse Large B Cell Lymphoma who Relapse after Autologous Stem Cell Transplantation and Receive Active Therapy. A Retrospective Analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Eva González-Barca, Ariane Boumendil, Didier Blaise, Marek Trněný, Tamas Masszi, Herve Finel, Mariagrazia Michieli, Jörg Bittenbring, Giuseppe Gritti, John Snowden, Mark Bishton et al. Bone Marrow Transplant. 2020 Feb;55(2):393-399. [IF 4.674]
  15. ***Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. Toby A. Eyre, Amy A. Kirkwood, Julia Wolf, Catherine Hildyard, Carolyn Mercer, Hannah Plaschkes, John Griffith, Paul Fields, Arief Gunawan, Rebecca Oliver, Stephen Booth, Nicolas Martinez-Calle, Andrew McMillan, Mark Bishton, Christopher P. Fox, Graham P. Collins, Chris S.R. Hatton Br J Haematol. 2019 Oct;187(2):185-194. doi: 10.1111/bjh.16070. Epub 2019 Jun 20. [IF 5.206] ***
  16. ***Front-line management of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) – a retrospective UK multicentre study. Matthew R. Wilson, Timothy Bagguley, Alexandra Smith, Eve Roman, Russell Patmore, Katharine Hanlon, Mike Leach, Mark Bishton, Cathy Burton, Pam McKay. Br J Haematol. 2019 Sep;186(6):e214-e217. [IF 5.206] ***
  17. COO and MYC/BCL2 status does not predict outcome among patients with PET-CT stage I/II DLBCL. Allison Barraclough, Musa Alzahrani, Marianne Schmidt Ettrup, Mark Bishton, Chris Van Vliet, Laurie H. Sehn, Vishakha Sovani, Mitchell Steven Ward, Bradley Augustson, Pedro Farinha, Jorne Lionel Biccler, Joseph M Connors, David W. Scott, Kerry J Savage, Tarec Christoffer El-Galaly, Diego Villa and Chan Yoon Cheah. Blood Adv. 2019 Jul 9;3(13):2013-2021. [IF 4.584]
  18. A Multi-Center Retrospective Comparison of Induction Chemoimmunotherapy Regimens on Outcomes in Transplant-eligible Patients with Previously Untreated Mantle Cell Lymphoma. Zi Yun Ng, Mark Bishton, David Ritchie, Robert Campbell, Michael Gilbertson, Kate Hill, Sumita Ratnasingam, Anthony Schwarer, Kate Manos, Sophie Shorten, Melissa Ng, Niles Nelson, Liu Xin, Sanjay De Mel Widanalage, Tenny Sunny, Duncan Purtill, Michelle Poon, Anna Johnston, Tara Cochrane, Hui‐Peng Lee, Greg Hapgood, Constantine Tam, Stephen Opat, Eliza Hawkes, John Seymour, Chan Yoon Cheah. Hematol Oncol. 2019 Apr 15. doi: 10.1002/hon.2618. [IF 3.439]
  19. Refractoriness to rituximab based therapy and the PRIMA PI predict for inferior survival in marginal zone lymphoma. Sorigue, Marc; Bishton, Mark; Domingo Domenech, Eva; Mcmillan, Andrew; Prusila, Roosa Enni Inkeri; Olga, Garcia; kuusisto, milla; condom, maria; Tapia, Gustavo Tapia; Ribera, Josep-Maria; Kuittinen, Outi; Fox, Christopher Paul; Sancho, Juan Manuel. Leuk Lymphoma. 2019 Apr 3:1-8. doi: 10.1080/10428194.2019.1594212. [IF 2.644].
  20. ***Male gender is an independent predictor for worse progression-free survival, overall survival and adjusted cumulative relapse risk in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP. Toby A. Eyre, Nicolas Martinez-Calle, Catherine Hildyard, David W. Eyre, Hannah Plaschkes, John Griffith, Julia Wolf, Paul A. Fields, Arief Gunawan, Rebecca Oliver, Stephen Booth, Andrew McMillan, Christopher P. Fox, Mark Bishton, Graham P. Collins, Chris S.R. Hatton. Br J Haematol. 2019 Aug;186(4):e94-e98. doi: 10.1111/bjh.15927. [IF 5.206] ***
  21. ***Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly DLBCL patients: no difference in cumulative incidence of relapse comparing patients by age. Eyre, Toby; Martinez-Calle, Nicolas; Hildyard, Catherine; Eyre, David; Plaschkes, Hannah; Griffith, John; Wolf, Julia; Fields, Paul; Gunawan, Arief; Oliver, Rebecca; Djebbari, Faouzi; Booth, Stephen; McMillan, Andrew; Fox, Christopher; Bishton, Mark; Collins, Graham; Hatton, Chris. J Intern Med. 2019 Jun;285(6):681-692. doi: 10.1111/joim.12889. [IF 6.754] ***
  22. Complete remission of immunochemotherapy-refractory monomorphic post-transplant lymphoproliferative disorder mediated by endogenous T-cell recovery. Mark J Bishton, Heather M Long, Alexander C Dowell, Benjamin J Meckiff, Catherine Byrne, Christopher P Fox. Leuk Lymphoma. 2019 Aug;60(8):2075-2078. doi: 10.1080/10428194.2019.1571203. Epub 2019 Feb 5. [IF 2.664]
  23. ***Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis. Martínez-Calle N, Hartley S, Ahearne M, Kasenda B, Beech A, Knight H, Balotis C, Kennedy B, Wagner S, Dyer MJS, Smith D, McMillan AK, Miall F, Bishton M, Fox CP. Br J Haematol. 2018 Dec 13. doi: 10.1111/bjh.15722. [Epub ahead of print] [IF 5.206] ***
  24. Population based study of Mantle Cell Lymphoma: Improvements in survival only seen in younger patients Komal Joshi, Richard Hubbard, Mark J Bishton. Hematol Oncol. 2018 Jan 24. doi: 10.1002/hon.2495. [IF 3.439]
  25. Excellent Outcome with Single Agent Methotrexate in Bone Marrow Biopsy defined Large Granular Lymphocytosis in a Single Centre. Tal Munhir, Mark J Bishton, Andrew K McMillan, Andrew P Haynes and Christopher P Fox. Clin Lymphoma Myeloma Leukaemia. 2016 Dec;16(12):705-712. [IF 2.494]
  26. ***The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naive patients with peripheral T-cell lymphoma: a systematic review of the literature. KD Jethwa, MJ Bishton and CP Fox. Br J Haematol. 2016 May 5. doi: 10.1111/bjh.14130. [Epub ahead of print]. [IF 5.67] ***
  27. Pre-Transplantation FDG-PET Predicts Early but not Late Survival Outcomes Following Allogeneic Transplantation in Chemo-Sensitive Hodgkin Lymphoma. Irfan Kayani, Ronjon Chakraverty, Adrian Bloor, Christopher P Fox, Kirsty Thomson, Adele K. Fielding, Ben Taylor, Mark J Bishton, Emma Morris, Nigel Russell, Stephen Mackinnon and Karl S Peggs. Biol BMT 2016 Apr 14. [IF 3.404]
  28. ***Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Reply to Adams and Kwee. Bishton MJ, McMillan AK, Fox CP. Br J Haematol. 2016 Mar 28. doi: 10.1111/bjh.14050. [IF 5.67] ***
  29. ***Delineating outcomes of patients with diffuse large B cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis. Bishton MJ, Hughes S, Richardson F, James E, Bessell E, Sovani V, Ganatra R, Haynes AP, McMillan AK, Fox CP. Br J Haematol. 2016 Jan;172(2):246-54. [IF 5.67] ***
  30. ***Era-by-Era Improvement in Survival for Elderly Patients with Hodgkin Lymphoma; Outcome data from a Large Population-based cohort. M.J. Bishton, R. Hubbard, R. Witherall, S.G. Jones, F. Richardson, E.J. James, V. Sovani, E.M. Bessell, A.P. Haynes, A.K. McMillan, C.P. Fox. Ann Oncol 2015 Nov;(11):2356-7 [IF 9.269]***
  31. EBV-driven relapse of angioimmunoblastic T cell lymphoma, masquerading as a post-transplant lympho-proliferative disorder following allogeneic stem cell transplantation. Christopher P Fox, Mark J Bishton, Simon O’Connor, Nigel Russell. Bone Marrow Transplant 2014 Jan;49(1):150-2 [IF 3.746]
  32. A Single Arm Phase II study of the anti-Blys Monoclonal Antibody Belimumab in Symptomatic Waldenstroms Macroglobulinaemia. Mark J Bishton, Andrew Spencer, Michael Dickinson, David Ritchie. Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):575-8 [IF 1.601]
  33. The Pan Histone Deacetylase Inhibitor Panobinostat and the Iso-selective Inhibitor Romidepsin reduce Glycoprotein VI expression and Inhibit Murine Platelet Response to Collagen Related Peptide. Mark J Bishton, EE Gardiner, Simon J Harrison, H Miles Prince, Ricky W Johnstone. Thromb Res. 2013 Jun;131(6):514-20. [IF 2.61]
  34. A focus on the pre-clinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax®). Simon J Harrison, Mark Bishton, Susan E. Bates, Steven Grant, Richard L. Piekarz, Ricky W. Johnstone, Yun Dai, Becki Lee, Maria E. Araujo, H. Miles Prince. Epigenomics. 2012. Oct;4(5):571-89 [IF 2.375]
  35. *** Deciphering the Molecular and Biological Processes that Mediate Histone Deacetylase Inhibitor-induced Thrombocytopenia. Mark J Bishton, Simon J Harrison, Benjamin P Martin, Nicole McLaughlin, Chloé James, Emma C Josefsson, Katya J Henley, Benjamin T Kile, H. Miles Prince, Ricky W Johnstone. Blood. 2011. Mar 31;117(13):3658-68 [IF 10.38] ***
  36. MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi). Burbury KL, Bishton MJ, Johnstone RW, Dickinson MJ, Szer J, Prince HM. Ann Hematol. 2011. Jul;90(7): 847-849. [IF 2.910]
  37. Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. Bishton MJ, Johnstone RW, Dickinson M, Harrison S, Prince HM. Pharmaceuticals 2010. Aug; 3(8) 2674-2688.
  38. What is responsible for the recent improvements in outlook for patients with follicular lymphoma? MJ Bishton, JF Seymour. Leuk Lymphoma 2010 Jun;51(6):960-2. [IF 1.939].
  39. Light chain deposition disease presenting as massive hepatomegaly. Nath S, Peiris M, Bishton MJ, Maxwell E, Prince, HM. Pathology 2010 Apr;42(3):307-10. [IF 2.234].
  40. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Dickinson M, Ritchie D, DeAngelo DJ,  Spencer A,  Ottmann OG,  Fischer T, Bhalla KP, Liu A, Parker K, Scott JW, Bishton M, Prince HM. Br J Haematol. 2009. Oct;147(1):97-101. [IF 4.478].
  41. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Prince HM, Bishton MJ, Johnstone RW. Future Oncol. 2009. Jun;5(5):601-12. [IF 2.455]
  42. *** Clinical studies of histone deacetylase inhibitors. Prince HM, Bishton MJ, Harrison SJ. Clin Cancer Res. 2009. Jun 15;15(12):3958-69. [IF 6.488] ***
  43. Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma. Hematology Meeting Reports HM Prince, M Bishton. 2009. 3(1): 33-38
  44. ***Claimed Association of Absolute Lymphocyte Count with Therapeutic Efficacy of Radio-Immunotherapy in Patients with Indolent Lymphoma cannot be verified in an Independent Data Set. MJ Bishton, RJ Hicks, HM Prince, DS Ritchie, M Wolf, JF Seymour. Leukaemia 2008 Dec; 22(12):2259-60 [IF 8.634]***
  45. Repeat treatment with Iodine-131-Rituximab is Safe and Effective in Patients with Relapsed Indolent B-Cell Non Hodgkin’s Lymphoma who had Previously responded to Iodine-131-Rituximab. Bishton MJ, Leahy MF, Hicks RJ, Turner JH, McQuillan AD, Seymour JF. Ann Oncol. 2008 Sep;19(9):1629-33. [IF 4.935]
  46. *** A Prospective Study of the Separate Predictive Capabilities of 18[F]-FDG-PET and Molecular Response in Patients with Relapsed Indolent Non Hodgkin Lymphoma following Treatment with Iodine-131-Rituximab Radio-immunotherapy. MJ Bishton, RJ Hicks, DA. Westerman, MH Prince, M Wolf, JF Seymour. Haematologica. 2008 May; 93(5):789-90. [IF 5.516] ***
  47. Histone Deacetylase Inhibitors in Lymphoma and Solid Malignancies. W Rasheed; M Bishton; RW. Johnstone, HM.Prince. Expert Rev Anticancer Ther. 2008 Mar;8(3);413-32. [IF 1.988]
  48. IVE is a more effective stem cell mobilisation regimen than ICE in the context of salvage therapy for lymphoma. Fox CP, McMillan AK, Bishton MJ, Haynes AP, Russell NH. Br J Haematol. 2008 Apr;141(2);244-8. [IF 4.49]
  49. The Potential of Histone Deacetylase Inhibitors for the Treatment of Multiple Myeloma. HM Prince, M Bishton, S Harrison. Leuk Lymphoma. 2008 Mar;49(3):385-7. [IF 1.512]
  50. Epigenetic Targets in Hematological Malignancies: Combination Therapies with HDACis and Demethylating Agents. Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince HM. Expert Rev Anticancer Ther. 2007 Oct;7(10):1439-49. [IF 1.988]
  51. Spinal Epidural Lipomatosis in Myeloma. Liew MS, Bishton MJ, Januszewicz H,Alatakis S, Prince HM Leuk Lymphoma. 2007 Oct;48(10):2068-70. [IF 1.512]
  52. High dose Melphalan or Tandem Intermediate dose Melphalan supported by PBSC results in comparable response rates in Elderly Patients over 65 Years with Myeloma. M Bishton, M Gilyead, E Das Gupta, C Williams, NH Russell, JL Byrne. Leuk Res. 2007 Aug;31(8):1063-8. [IF 2.561]
  53. Ifosphamide, Etoposide and Epirubicin is an effective combined Salvage and Peripheral Stem Cell Mobilisation regimen for transplant eligible Patients with Non Hodgkins disease and Hodgkins Lymphoma. M Bishton, R Lush, NH Russell, JL Byrne, BE Shaw AP Haynes. Br J Haematol. 2007 Mar;136(5):752-61. [IF 4.49]
  54. Combination Chemotherapy followed by Autologous Stem Cell Transplant for Enteropathy Associated T cell Lymphoma. M Bishton, AP Haynes. Br J Haematol. 2007 Jan;136(1):111-3. [IF 4.49]
  55. Opsoclonus Myoclonus following Allogeneic Haematopoietic Stem Cell  Transplantation. MJ Bishton, E Das Gupta, JL Byrne, NH Russell. Bone Marrow Transplant. 2005 Nov; 36(10):923. [IF 3.0]
  56. The Role of Granulocyte Transfusions in Neutropenic Patients. M Bishton, R Chopra. Brit J Haematol. 2004 Dec;127(5):501-8. [IF 4.49]
 
 
zurück zur Übersicht
Corporate Partners - Individual Sponsors
Mon, 20th June 2022 to Tue, 21th June 2022
Phase I/II Meeting
more dates
Mon, 24th January 2022
New members of the European MCL board
more news